RxDoctor Payments Data

Jose Anzaldua, MD

Family Medicine · Sugar Land, TXNPI 1659353001

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 25 payments — averaging $64.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$614
  • AstraZeneca$355
  • Amarin Pharma, Inc.$139
  • Boston Scientific$138
  • AbbVie$118
  • Lilly USA, LLC$115
  • plus $136 from 3 others

What the payments were for

  • Food & beverage$1,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,129
Medicare patients
292
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$58,222
FarxigaDapagliflozin Propanediol53$52,723
OzempicSemaglutide40$49,891
TrulicityDulaglutide20$35,339
MresviaRsv Vaccine, Pref, Mrna/Pf115$33,850
JanuviaSitagliptin Phosphate33$32,763
JanumetSitagliptin Phos/Metformin Hcl23$29,362
Olmesartan Medoxomil329$7,572
Icosapent Ethyl13$6,628
Atorvastatin Calcium573$4,276
Amlodipine-ValsartanAmlodipine Besylate/Valsartan40$3,732
Valsartan159$3,696
Metformin Hcl395$2,998
Levothyroxine Sodium312$2,906
SynthroidLevothyroxine Sodium32$2,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$355$52,72353 claims
Novo NordiskOzempic$614$49,89140 claims
Lilly USA, LLCTrulicity$115$35,33920 claims
AbbVieSynthroid$118$2,50332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →